UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020June 30, 2021

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

[  ]For the transition period fromTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934to

For the transition period from                   to                   

Commission File No. 000-56100000-40403

SAVE FOODS, INC.

(Exact name of registrant as specified in its charter)

 

SAVE FOODS, INC.Delaware26-4684600
(Exact name of registrant as specified in its charter)

Delaware26-468460

(State or other jurisdiction

of

(I.R.S. Employer
incorporation or organization)

(I.R.S. Employer

Identification No.)

Habarzel 7KibbutzAlonim
Tel Aviv, Israel69710113657700
(Address of Principal Executive Offices)(Zip Code)

+972 72 2116144
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

(347)468 9583

(Registrant’s telephone number, including area code)

n/a

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of exchange on which registered
N/ACommon Stock, Par value $0.0001 per shareN/ASVFDN/AThe NasdaqCapital Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

[  ]Large accelerated filer[  ]Accelerated filer
[X]Non-accelerated filer[X]Smaller reporting company
[  ]Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

AsThe number of March 31, 2020,shares of the registrant had 10,209,487shares ofregistrant’s common stock, $0.0001 par value, $0.0001,outstanding as of the registrant issued and outstanding.August 11, 2021: 2,790,836.

As used in this Quarterly Report and unless otherwise indicated, the terms “Save Foods,” “we,” “us,” “our,” or “our Company” refer to Save Foods, Inc. and Save Foods Ltd., our 98.48% owned subsidiary. Unless otherwise specified, all dollar amounts are expressed in United States dollars.

 

 
 

Save Foods, Inc.

Quarterly Report on Form 10-Q

TABLE OF CONTENTS

Page
Cautionary Note Regarding Forward-Looking Statements3
PART 1-FINANCIALI - FINANCIAL INFORMATION
Item 1.Unaudited Consolidated Financial Statements (unaudited)4
Unaudited Consolidated Balance Sheets75
Unaudited Consolidated Statements of Comprehensive Loss86
Unaudited Statements of Stockholders’ Equity97
Unaudited Consolidated Statements of Cash Flows108
Notes to Consolidated Financial Statements119
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16
Item 3.Quantitative and Qualitative Disclosures about Market Risk1822
Item 4.Control and Procedures1822
PART II-OTHERII - OTHER INFORMATION
Item 1A.Risk Factors1923
Item 6.Exhibits2023
SIGNATURES2124

2
 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise;
sales of our products;
the size and growth of our product market;
our activity in the civilian market;
our manufacturing capabilities;
our entering into certain partnerships with third parties;
obtaining required regulatory approvals for sales or exports of our products;
our marketing plans;
our expectations regarding our short- and long-term capital requirements;
our expectation regarding the effectimpact of COVID-19 on our business;business and operations;
our outlook for the coming months and future periods, including but not limited to our expectations regarding future revenue and expenses; and
information with respect to any other plans and strategies for our business.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 20192020 (filed on March 30, 2020)29, 2021) (“2020 Annual Report”) entitled “Risk Factors” as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

On February 23, 2021, we implemented a one-for-seven reverse stock split of our common stock, par value $0.0001 per share (the “Common Stock”) pursuant to which holders of our Common Stock received one share of our Common Stock for every seven shares of Common Stock held. Unless the context expressly dictates otherwise, all references to share and per share amounts referred to herein reflect the reverse stock split.

3
 

PART I – FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS.

SAVE FOODS, INC.

INTERIMCONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2020JUNE 30, 2021

UNAUDITEDIN U.S. DOLLARS

INDEXTABLE OF CONTENTS

Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Unaudited Condensed Consolidated Balance Sheets as of June 30, 2021, and December 31, 202075
Unaudited Condensed Consolidated Statements of Comprehensive Loss for the Six and Three Months Ended June 30, 2021 and June 30, 202086
Unaudited Condensed Consolidated Statements of Shareholders’ Deficit for the Six and Three Months period Ended June 30, 2021 and June 30, 20207
Statements of Stockholders’ Equity9
Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and June 30, 2020108
Notes to Unaudited Condensed Consolidated Financial Statements119 - 15

4
 

 

SAVE FOODS, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2020

5

SAVE FOODS, INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2020

IN U.S. DOLLARS

TABLE OF CONTENTS

Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:
Condensed Consolidated Balance sheets as of March 31, 2020 (unaudited), and December 31, 20197
Condensed Consolidated Statements of Comprehensive Loss for three months ended March 31, 2020 and 2019 (unaudited)8
Condensed Consolidated Statements of stockholders’ deficit for the period of three months ended March 31, 2020 (unaudited) and the year ended December 31, 20199
Condensed Consolidated Statements of cash flows for the three months ended March 31, 2020 and 2019 (unaudited)10
Notes to unaudited condensed consolidated financial statements11-15

6

SAVE FOODS, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars except share and per share data)

 March 31, December 31,  2021 2020 
 2020 2019  June 30, December 31, 
  (Unaudited)      2021  2020 
Asse t s        
Assets        
Current Assets                
Cash and cash equivalents  180,003   290,815   9,305,800   242,900 
Restricted Cash  37,027   38,194 
Restricted cash  22,086   22,395 
Accounts receivable, net  -   64,003   54,403   147,941 
Inventories  11,267   16,302   15,236   16,356 
Other current assets  26,159   15,300   706,258   65,579 
Total Current assets  254,456   424,614   10,103,783   495,171 
                
Right Of Use asset arising from operating lease  37,314   48,982 
Right of use asset arising from operating lease  6,963   14,700 
                
Property and Equipment, Net  73,703   81,119 
Property and equipment, net  45,585   55,194 
                
Funds in Respect of Employee Rights Upon Retirement  109,871   109,955 
Funds in respect of employee rights upon retirement  118,209   122,584 
Total assets  475,344   664,670   10,274,540   687,649 
                
Liabilities and Shareholders’ Deficit        
Liabilities and Shareholders’ Equity ( Deficit)        
Current Liabilities                
Short-term loan from banking institution  7,049   7,230   7,928   7,949 
Current maturities of convertible loans  -   56,250 
Accounts payable  219,145   235,864   329,253   203,323 
Other accounts liabilities  392,148   380,732 
Other liabilities  862,415   517,711 
Total current liabilities  618,342   623,826   1,199,596   785,233 
Convertible Loans  403,011   285,917 
Long term from banking institution  12,717   14,955 
  142,357   142,142 
Fair value of convertible component in convertible loans  -   54,970 
Convertible loans  -   146,929 
Long term loan from banking institution  3,995   8,115 
Liability for employee rights upon retirement  142,357   142,091   152,992   157,855 
                
Total liabilities  1,176,427   1,066,789   1,356,583   1,153,102 
                
Stockholders’ Deficit        
Common stocks of US$ 0.0001 par value each (“Common Stocks”):
495,000,000 shares authorized as of March 31, 2020 and December 31, 2019; issued and outstanding 10,209,487 shares as of March 31, 2020 and December 31, 2019.
  1,021   1,021 
Preferred stocks of US$ 0.0001 par value (“Preferred stocks”):
5,000,000 shares authorized as of March 31, 2020 and December 31, 2019; issued and outstanding 0 shares as of March 31, 2020 and December 31, 2019.
  -   - 
Stockholders’ Equity        

Common stock, par value $ 0.0001 per share (“Common Stocks”):

495,000,000 shares authorized as of June 30, 2021 and December 31, 2020; issued and outstanding 2,776,551 shares as of June 30, 2021 and 1,606,765 shares as of December 31, 2020.

  278   161 
Preferred stock, par value $ 0.0001 per share (“Preferred stock”): 5,000,000 shares authorized as of June 30, 2021 and December 31, 2020; issued and outstanding 0 shares as of June 30, 2021 and December 31, 2020.  -   - 
Additional paid-in capital  10,398,420   10,328,696   23,244,172   11,867,585 
Foreign currency translation adjustments  (26,275)  (26,275)  (26,275)  (26,275)
Accumulated deficit  (11,050,155)  (10,684,508)  (14,251,490)  (12,277,647)
  (676,989)  (381,066)
Stockholders' Equity  8,966,685   (436,176)
Non-controlling interests  (24,094)  (21,053)  (48,728)  (29,277)
Total stockholders’ deficit  (701,083)  (402,119)
Total liabilities and stockholders’ deficit  475,344   664,670 
Total stockholders’ equity (deficit)  8,917,957   (465,453)
Total liabilities and stockholders’ equity (deficit)  10,274,540   687,649 

The accompanying notes are an integral part of the condensed consolidated financial statements.

75
 

SAVE FOODS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars except share and per share data)

 Three months ended  2021 2020 2021 2020 
 March 31  Six months ended Three months ended 
 2020  2019  June 30 June 30 
 (Unaudited)  2021 2020 2021 2020 
              
Revenues from sales of products  63,566   129,733   177,477   63,566   54,403   - 
Cost of sales  (20,775)  (34,041)  (14,287)  (25,686)  (11,354)  (4,911)
Gross profit  42,791   95,692 
Gross profit (loss)  163,190   37,880   43,049   (4,911)
Research and development expenses  (157,636)  (131,826)  (296,533)  (253,343)  (226,742)  (95,707)
Selling and marketing expenses  (28,937)  (146,562)  (33,409)  (36,748)  (18,712)  (7,811)
General and administrative expenses  (218,079)  (163,148)  (1,672,707)  (513,376)  (1,419,736)  (295,297)
Operating loss  (361,861)  (345,844)  (1,839,459)  (765,587)  (1,622,141)  (403,726)

Financing expenses, net

  (7,202  (13,502)
Financing income (expenses), net  (156,061)  (200,351)  120,916   (193,149)
Gain on disposal of affiliated company  -   15,690   -   15,690 
Net loss  (369,063)  (359,346)  (1,995,520)  (950,248)  (1,501,225)  (581,185)
                
Less: Net loss attributable to non-controlling interests  3,416   3,584   21,677   7,556   19,784   4,140 
Net loss attributable to the Company  (365,647)  (355,762)  (1,973,843)  (942,692)  (1,481,441)  (577,045)
                        
Loss per share (basic and diluted)  (0.04)  (0.04)  (1.05)  (0.65)  (0.69)  (0.40)
                        
Basic and diluted weighted average number of shares of common stock outstanding  10,209,487   

9,521,981

 
Basic and diluted weighted average number of shares of Common Stock outstanding (1)  1,884,365   1,458,598   2,158,915   1,458,598 

(1)Prior periods results have been adjusted to reflect 7 to 1 reverse stock split in February 2021 (see note 1).

The accompanying notes are an integral part of the condensed consolidated financial statements.

86
 

SAVE FOODS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

EQUITY (DEFICIT)

(U.S. dollars, except share and per share data)

  Share  Amt  Amt  Amt  Amt  Amt  Amt  Amt  Total 
  

Number

of Shares

  Amount  

Additional

paid-in

capital

  

Accumulated

other

comprehensive

income (loss)

  

Proceeds on

account of

shares

  

Accumulated

deficit

  

Total

Company’s

stockholders’

deficit

  

Non-

controlling

interests

  

Total

stockholders’

deficit

 
                            
BALANCE AT JANUARY 1, 2020  1.458.598   146   10,329,571   (26,275)  -   (10,684,508)  (381,066)  (21,053)  (402,119)
Receipts on account of shares                                    
Stock based compensation  -   -   35,028   -   -   -   35,028   375   35,403 
Value of warrant issued in convertible loans  -   -   34,696   -   -   -   34,696   -   34,696 
Issuance of shares, net of issuance costs of $1,542,138                                    
Conversion of convertible loans                                    
Share based compensation for services providers                                    
Comprehensive loss for three months ended March 31, 2020  -   -   -   -   -   (365,647)  (365,647)  (3,416)  (369,063)
BALANCE AT JUNE 30, 2020  1,458,598   146   10,399,295   (26,275)  -   (11,050,155)  (676,989)  (24,094)  (701,083)
Receipts on account of shares  -   -   -   -   100,000   -   100,000   -   100,000 
Stock based compensation  -   -   182,313   -   -   -   182,313   1,951   184,264 
Conversion of convertible loans  -   -   585,931   -   -   -   585,931   -   585,931 
Comprehensive loss for three months ended June 30, 2020  -   -   -   -   -   (577,045)  (577,045)  (4,140)  (581,185)
BALANCE AT JUNE 30, 2020  1,458,598   146   11,167,539   (26,275)  100,000   (11,627,200)  (385,790)  (26,283)  (412,073)

  

Number

of shares

  Amount  

Additional

paid-in

capital

  

Accumulated

other

comprehensive

income (loss)

  Proceeds on account of shares  

Accumulated

deficit

  

Total

Company’s

stockholders’

equity

  

Non-

controlling

interests

  

Total

stockholders’

equity

 
                            
BALANCE AT JANUARY 1, 2021  1,606,765   161   11,867,585   (26,275)  -   (12,277,647)  (436,176)  (29,277)  (465,453)
Stock based compensation  -   -   83,605   -   -   -   83,605   895   84,500 
Comprehensive loss for three months ended March 31, 2021  -   -   -   -   -   (492,402)  (492,402)  (1,893)  (494,295)
BALANCE AT MARCH 31, 2021  1,606,765   161   11,951,190   (26,275)  -   (12,770,049)  (844,973)  (30,275)  (875,248)
Issuance of shares, net of issuance costs of $1,542,138  1,090,909   109   10,457,753   -   -   -   10,457,862   -   10,457,862 
Conversion of convertible loans  66,877   7   648,403   -   -   -   648,410   -   648,410 
Stock based compensation  -   -   60,227   -   -   -   60,227   1,331   61,558 
Share based compensation for services providers  12,000   1   126,599   -   -   -   126,600   -   126,600 
Comprehensive loss for three months ended June 30, 2021  -   -   -   -   -   (1,481,441)  (1,481,441)  (19,784)  (1,501,225)
Comprehensive loss  -   -   -   -   -   (1,481,441)  (1,481,441)  (19,784)  (1,501,225)
BALANCE AT JUNE 30, 2021 (1)  2,776,551   278   23,244,172   (26,275)  -   (14,251,490)  8,966,685   (48,728)  8,917,957 

 

  Number of Shares  Amount  Additional paid-in capital  Accumulated other comprehensive income (loss)  Proceeds on account of shares  Accumulated deficit  Total Company’s stockholders’ equity  Non-controlling interests  Total
stockholders’ deficit
 
                            
BALANCE AT DECEMBER 31, 2018  9,228,339   923   8,851,670   (26,275)  105,000   (8,713,091)  218,227   (6,712)  211,515 
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2019:                                    
Issuance of shares for cash  605,563   61   561,606       (105,000)      456,667   -   456,667 
Stock based compensation          67,235               67,235   720   67,955 
Comprehensive loss for three month ended March 31, 2019                      (355,762)  (355,762)  (3,584)  (359,346)
BALANCE AT MARCH 31, 2019 (Unaudited)  9,833,902   984   9,480,511   (26,275)  -   (9,068,853)  386,367   (9,576)  376,791 
(1)Prior periods results have been adjusted to reflect 7 to 1 reverse stock split in February 2021 (see note 1).

 

  Number of Shares  Amount  Additional paid-in capital  Accumulated other comprehensive income (loss)  Proceeds on account of shares  Accumulated deficit  Total
Company’s stockholders’ equity
  Non-controlling interests  Total
stockholders’ deficit
 
BALANCE AT DECEMBER 31, 2019  10,209,487   1,021   10,328,696   (26,275)  -   (10,684,508)  (381,066)  (21,053)  (402,119)
CHANGES DURING THE PERIOD OF THREE MONTHS ENDED MARCH 31, 2020:                                    
Value of warrant issued in convertible loans          34,696               34,696       34,696 
Stock based compensation          35,028               35,028   375   35,403 
Comprehensive loss for three month ended March 31, 2020                      (365,647)  (365,647)  (3,416)  (369,063)
BALANCE AT MARCH 31, 2020 (Unaudited)  10,209,487   1,021   10,398,420   (26,275)  -   (11,050,155)  (676,989)  (24,094)  (701,083)

The accompanying notes are an integral part of the condensed consolidated financial statements.

97
 

SAVE FOODS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars except)except share and per share data)

 Three months ended  2021  2020 
 March 31,  Six months ended 
 2020  2019  June 30, 
 (Unaudited)  2021  2020 
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net loss for the period  (369,063)  (359,346)
Loss for the period  (1,995,520)  (950,248)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:                
Depreciation and amortization  19,084   3,757   17,346   25,934 

Increase in liability for employee rights upon retirement

  266   6,021 
Gain on disposal of affiliated company  -   (15,690)
Increase (decrease) in liability for employee rights upon retirement  (4,863)  4,332 
Stock based compensation  35,403   67,955   272,658   219,667 

Interest on convertible loans

  17,325   1,011 
Decrease (increase) in accounts receivable  64,003   (27,211)
Expenses on convertible loans  115,972   141,926 
Conversion of convertible loans      57,793 
Decrease in accounts receivable  93,538   64,003 
Decrease in inventory  5,035   12,441   1,120   5,035 
Increase in other current assets  (10,859)  (20,377)  (680,679)  (30,516)
Decrease in accounts payable  (16,719)  (50,669)
Increase (decrease) in accounts payable  117,786   (55,428)

Increase in other accounts payable

  21,889   39,524   351,420   64,193 
Net cash used in operating activities  (233,636)  (326,894)  (1,711,222)  (468,999)
                
CASH FLOWS FROM INVESTING ACTIVITIES:                
Increase (decrease) in funds in respect of employee rights upon retirement  84   (4,484)
Net cash provided by (used in) investing activities  84   (4,484)
Payments on investment in unconsolidated entity  -   2,480 
Decrease (increase) in funds in respect of employee rights upon retirement  4,375   (3,054)
Net cash provided by investing activities  4,375   (574)
                
CASH FLOWS FROM FINANCING ACTIVITIES:                
Secured promissory notes  135,000   - 
Proceeds from secured promissory notes  274,000   135,000 
Proceeds on account of shares  -   100,000 

Repayments of right to use asset arising from operating lease

  (10,473)  -   (6,407)  (17,435)
Repayments of long term banking institute  (1,787)  (5,795)
Proceeds from stock issued for cash  -   456,667 
Repayments of long-term banking institutes  (3,852)  (3,556)
Proceeds from stock issued for cash, net of issuance costs of $1,502,138  10,497,862   - 
Net cash provided by financing activities  122,740   450,872   10,761,603   214,009 
Effect of exchange rate changes on cash and cash equivalents and restricted cash  8,144   - 
                
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS  (110,812)  119,494   9,062,900   (255,564)
                
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD  290,815   439,806   242,900   290,815 
                
CASH AND CASH EQUIVALENTS AT END OF PERIOD  180,003   559,300   9,305,800   35,251 
                
Supplemental disclosure of cash flow information:                
Non cash transactions:                
Issuance of shares in exchange for proceeds received in prior periods  -   105,000 
Disposal of affiliated company  -   5,087 
Issuance of warrants in convertible loans  34,696      -   34,696 
Conversion of convertible loans  648,410   528,138 
Deferred issuance expenses  40,000   - 

The accompanying notes are an integral part of the condensed consolidated financial statement

108
 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 1 - GENERAL

Save Foods, Inc. (the “Company”) was incorporated on April 1, 2009, under the laws of the State of Delaware. On April 27, 2009, the Company acquired from its stockholders all 98.48% of the issued and outstanding shares of Save Foods Ltd (formerly Pimi Agro Cleantech Ltd). (hereinafter: “Save Foods Israel”)Ltd., an Israeli company, including preferred and ordinary shares.

Common Stock. Save Foods IsraelLtd. was incorporated in 2004 and commenced its operations in 2005. Save Foods IsraelLtd. develops, produces, and focuses on delivering innovative solutions for the food industry aimed at improving food safety and prolonging shelf life of fresh produce.

In February 2010,Through May 13, 2021, the Company’s shares of common stock began quotation on the OTC Bulletin Board under the symbol “PIMZ.OB”. As of the date of the financial statements the Company’s shares of common stock areCommon Stock was quoted on the OTC, Pink Tier, under the symbol “SAFO”.

Going Concern

Since its incorporation (April 1, 2009), On May 13, 2021, the Company has not had any operations other than those carried out by Save Foods Israel. The development and commercializationcompleted an underwritten public offering of Save Foods Israel’s products will require substantial expenditures. Save Foods Israel and1,090,909 shares of Common Stock of the Company have not yet generated sufficient revenues from their operationsat a price to fund the Group activities and are therefore dependent upon external sources for financing their operations. There can be no assurance that Save Foods Israel and the Company will succeed in obtaining the necessary financing to continue their operations. Aspublic of March 31, 2020, the Company had $180,003 in cash, a negative working capital of $363,886 and an accumulated deficit of $11,050,155.

$11.00per share. The Company will need to secure additional capital in the future in order to meet its anticipated liquidity needs primarily through the sale of additional Common Stock or other equity securities and/or debt financing. Funds from these sources may not be availablegross proceeds to the Company on acceptable terms, if at all,from this offering were $12,000,000, before deducting underwriting discounts, commissions and other offering expenses, and excluding the exercise of the over-allotment option by the underwriter, which were not exercised. The Company granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock of the Company cannot give assurance that it will be successful in securing such additional capital.

The Company focuses its solutions towards vegetablesto cover over-allotments at the public offering price, less the underwriting discounts and fruitscommissions, which are consideredwas not exercised by the largest in terms of worldwide consumption. Among other things,underwriter. In addition, the Company triesissued to cooperate with major fruit packing housesthe underwriter as compensation warrants to purchase up to 54,545 shares of Common Stock (5% of the aggregate number of shares of Common Stock sold in Israelthis offering exclusive of the over-allotment option, or the underwriter’s warrants). The underwriter’s warrants are exercisable at a per share exercise price equal to 125% of the public offering price per share in the offering, or $13.75 per share.The underwriter’s warrants are exercisable at any time and abroad. Asfrom time to time, in whole or in part, during the four one half year period commencing 180 days from the effective date of balance sheet date, the Company had not signed any significant agreements.registration statement.

These factors raise substantial doubt about Save Foods Israel andCommencing on May 14, 2021, the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result fromCommon Stock was initially listed on the outcome of this uncertainty.Nasdaq Capital Market under the symbol “SVFD”.

OnIn March 11, 2020, the World Health Organization declared the coronavirus (COVID-19) outbreak a global pandemic. To date, the impact of the pandemic on the Company’s operations has been mainly limited to a temporary facility closure in the context of a novel coronavirus (SARS-CoV-2)government-mandated general lockdown, which temporary delayed certain development activities. Due to be a global pandemic (COVID-19)the effects of COVID-19, as of the date of this report, some of Company's employees are on temporary leave without pay (furlough), which continuesincluding Company's Chief Technology Officer, and we have postponed some of our planned field tests due to spread throughout the United Statescurrent restriction on international travels. However, to date, the Company did not experience any material impact on our financial condition and aroundresults of operations due to COVID-19 However, the world. TheCompany is unable to assess with certainty the extent of future impact, in part due to the uncertainty regarding the duration of the COVID-19 pandemic, is having significantits force and its effects on globalthe markets supply chains, businesses,in which the Company operates and communities. Specificthe effects of possible government measures to prevent the spread of the virus.

Reverse Stock Split

On February 23, 2021, the Company amended its Certificate of Incorporation to effect a 7 to 1 reverse stock split of the Company’s outstanding Common Stock.

As a result of the reverse stock split, every 7 shares of the Company’s outstanding Common Stock prior to the Company, COVID-19 may impact various partseffect of its 2020 operationsthat amendment were combined and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following the reverse split. The number of authorized capital of the Company’s Common Stock and par value of the shares remained unchanged.

All share, stock option and per share information in these condensed consolidated financial results including but not limitedstatements have been restated to reduction in sales, difficulties in obtaining additional financing, or potential shortages of personnel. The Company believes it is taking appropriate actions to mitigatereflect the negative impact. However, the full impact of COVID-19 is unknown and cannot be reasonably estimated as these events occurred subsequent to year end and are still developing.stock split on a retroactive basis.

119
 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Unaudited Interim Financial Statements

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiary, prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the instructions to Form 10-Q.. In the opinion of management, the financial statements presented herein have not been audited by an independent registered public accounting firm but include all material adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary for a fair statement of the financial condition, results of operations and cash flows for the for three-monthsthree and six-months ended March 31,June 30, 2021 and 2020. However, these results are not necessarily indicative of results for any other interim period or for the year ended December 31, 2020.2021. The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions for the reporting periods covered by the financial statements. These estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses. Actual amounts could differ from these estimates.

Certain information and footnote disclosures normally included in financial statements in accordance with generally accepted accounting principles have been omitted pursuant to the rules of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on published on the OTCIQ Alternative Reporting System,Form 10-K for the year ended December 31, 20192020.

Principles of Consolidation

The consolidated financial statements are prepared in accordance with US GAAP. The consolidated financial statements of the Company include the Company and its wholly-owned and majority-owned subsidiaries.subsidiary. All inter-company balances and transactions have been eliminated.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United StatesU.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to the going concern assumptions and convertible loans.share based compensation.

1210
 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Recent Accounting Pronouncements

In June 2016, FASBAugust 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”2020-06”). The guidance in ASU 2020-06 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In November 2018, FASB issuedaddition, the amendments in the ASU No. 2018-19, “Codification Improvements2020-06 also simplify the guidance in ASC Subtopic 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to Topic 326, Financial Instruments-Credit Losses”,classify a contract as equity, which amends the scope and transition requirements of ASU 2016-13. Topic 326 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amountis expected to be collected. The measurementdecrease the number of expected credit losses is basedfreestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectabilitycalculating earnings per share, requiring use of the reported amount. Topic 326 will originally becomeif-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The amendments in ASU 2020-06 are effective for the Company beginning January 1, 2020, with early adoption permitted, on a modified retrospective approach. As a smaller reporting company, the effective date for the Company has been delayed until fiscal years beginning after December 15, 2022, in accordance with ASU 2019-10, although early adoption is still permitted. This standard is not expected to have a material impact to the Company’s consolidated financial statements after evaluation.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in this ASU simplify the accounting for income taxes, eliminates certain exceptions to the general principles in Topic 740 and clarifies certain aspects of the current guidance to improve consistent application among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021 and interim periods within annual periods beginning after December 15, 2022, though early2021. Early adoption is permitted, including adoption in any interim period for which financial statements havepermitted. The guidance must be adopted as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this new guidance, but does not yet been issued. This standard is not expectedexpect it to have a material impact to the Company’s consolidatedon its financial statements after evaluation.statements.

NOTE 3 – CONVERTIBLE LOANS

In December 2019,On September 21, 2020, the Company entered into a series of Convertible Loan Agreements (each a “CLA”)convertible loan agreements with third parties and certain existing shareholders (the “Lenders”), pursuantlenders to which the Lenders agreed to provide the Company loans in the aggregate amount of $379,000 and in exchange the Company issued to the Lenders (i)sell convertible promissory notes (the “Notes”) and (ii) warrants with an exercise price of $1.20. In January and March 2020, the Company entered into two additional CLA agreements in the aggregate principal amount of $135,000, in the same terms.

The Notes will bear interest at a rate of 5% per annum. The loan amount represented by the Notes will be repaid to the Lenders according to the following schedule: (i) the principal amount represented by the Notes will be repaid in twenty four equal monthly installments, commencing on the twenty fifth month following the closing of each CLA and (ii) the interest accrued on the loan amount will be paid in two bi-annual installments, commencing on the first anniversary of the first payment of the principal amount.

$125,000. The outstanding loan amount of these convertible promissory notes will mature on the earlier of (i) the third anniversary of each CLAsuch convertible loan agreement or (ii) a deemed liquidation event, (as defined therein), and the Lenderslenders may convert all or any portion of the Notes at any time prior to the one-year anniversary of each issuanceconvertible promissory notes into shares of Common Stock at any time prior to a mandatory conversion event at a conversion price of US$1.20 $7.63 per share.share (collectively the “September 2020 CLAs”).

During October 2020, the Company entered into a series of additional convertible loan agreements with additional lenders to sell notes with an aggregate principal amount of $100,000, pursuant to the same terms a set forth in the September 2020 CLAs.

During January 2021, the Company entered into a series of additional convertible loan agreements with additional lenders to sell notes with an aggregate principal amount of $274,000, pursuant to the same terms a set forth in the September 2020 CLAs.

As part of the foregoing convertible loan agreements, the Company entered into registration rights agreements with each of the lenders, whereby each lender received piggyback registration rights for the shares of Common Stock issuable upon conversion of the notes.

On May 11, 2021 and May 12, 2021, the lenders of the convertible loans agreements utilized their optional conversion, of the entire balance of the convertible promissory notes in the aggregate principal amount of $499,000 and of aggregated accrued interest amount of $11,211, at a conversion price of $7.63 per share and the Company issued to the lenders an aggregate amount of 66,877 shares of Common Stock following the conversion.

1311
 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 34CONVERTIBLE LOANS (continue)COMMON STOCK

In accordance with ASC 815-15-25On May 13, 2021, the conversion feature was considered embedded derivative instruments, and is to be recorded at their fair value as its fair value can be separated from the convertible loan and its conversion is independentCompany completed an underwritten public offering of 1,090,909 shares of Common Stock of the underlyingCompany at a price to the public of $11.00 per share – see note value.1 above.

On May 15, 2021, the Company signed consulting agreement with a third party according to which the Consultant will provide the Company with investor relations services for a period of 12 months following the commencement date. As consideration for the agreement, the Company will pay the consultant an annual fee of $40,000 and issue the consultant 12,000 shares of Common Stock of the Company. On June 20, 2021, the Company issued 12,000 shares of Common Stock of the Company to the consultant. The Company recorded finance expenses in respect ofestimated the convertible component in the convertible loan in the excess amount of the convertible component fair value over the face loan amount. The conversion liability is then marked to market each reporting period with the resulting gains or losses shown in the statements of operations.

As a result of the above issuances, the Company recorded in the periods ended March 31, 2020 and December 31, 2019 a total amounts of US$34,696 and US$97,406, respectively, in respect of the detachable warrants, as a credit to stockholders’ equity (additional paid in capital). The fair value of the Warrants was determined using the Black-Scholes pricing model, assuming a risk free rate of 1.6%, a volatility factor of 54.00 %, dividend yields of 0 % and an expected life of 3 years. During the periods ended March 31, 2020 and December 31, 2019, the Company recorded interest and amortization expenses in the amounts of $16,790 and $4,323, respectively, in respect of the discounts recorded on the debentures.shares issue at $126,600.

NOTE 45STOCK OPTIONS

The following table presents the Company’s stock option activity for employees, directors and directorsconsultants of the Company for the threesix months ended March 31, 2020:June 30, 2021:

SCHEDULE OF STOCK OPTION ACTIVITY

 Number of Options  Weighted Average Exercise Price  

Number of

Options

 

Weighted

Average

Exercise Price

 
Outstanding at December 31,2019  1,150,004   0.45 
Outstanding at December 31,2020  206,862   3.37 
Granted  -   0.45   -   - 
Exercised  -   -   -   - 
Forfeited or expired  (58,333)  0.45   -   - 
Outstanding at March 31,2020  1,091,671   0.45 
Number of options exercisable at March 31, 2020  625,002   - 
Outstanding at June 30,2021  206,862   3.37 
Number of options exercisable at June 30, 2021  139,543   3.31 

The aggregate intrinsic value of the awards outstanding as of March 31, 2020June 30, 2021 is US$491,252.$941,627. These amounts represent the total intrinsic value, based on the Company’s stock price of US$ 0.9$ 7.92 as of March 31, 2020,June 30, 2021, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.

Costs incurred in respect of stock-based compensation for employees and directors, for the threesix months ended March 31,June 30, 2021 and 2020 were $146,058 and 2019 were $35,403$219,667 respectively

12

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 6 – COMMITMENT AND CONTINGENT LIABILITIES

A.On June 15, 2021, the Company signed consulting agreement with a third party according to which the consultant will provide the Company with public relations services. Based on the agreement the Company will pay the consultant a monthly fee of $3,500 and shall issue the consultant 200 shares of Common Stock of the Company on the final day of each month following the commencement date of the agreement.
B.On June 1, 2021, the Company terminated consulting agreements previously executed on October 10, 2018, with two of its consultants and signed new consulting agreements with the same parties. According to the agreements, the consultants shall provide the Company with business development and strategic consulting services including ongoing consulting for the Company, board and management. The agreement shall be effective until terminated by each of the parties by giving a 30 days prior notice. Based on the agreements, the Company agreed to pay each a monthly fee of $13,000 and $2,000 as monthly reimbursement of expenses. In addition, the Company agreed to grant the consultants with signing bonuses in the amounts of $150,000 and $250,000 net of the outstanding debt of the Company, which was $33,000 payable to each consultant. In addition, the Company agreed to pay the consultants 5% of any gain generated by the Company exceeding an initial gain of 25% due to any sale, disposition or exclusive license of activities, securities, business, or similar events initiated by each the Consultants. In addition, each consultant shall be entitled to a special bonus upon the execution of business opportunities or upon other events the consultant assisted with (“Consultant Engagements”), authorized by the CEO or the Chairman of the Board. The special bonus shall not exceed two times each consultant’s monthly fee. As of the date of the financial statements, no such Consultant Engagements were executed.

NOTE 7 – RELATED PARTIES

A. Transactions and $67,955, respectivelybalances with related parties

SCHEDULE OF TRANSACTIONS AND BALANCES WITH RELATED PARTIES

  

Six months ended

June 30

 
  2021  2020 
       
General and administrative expenses:        
Directors compensation (*)  22,217   228,136 
Salaries and fees to officers (*)  70,145   135,339 
General and administrative expenses, net  92,362   363,475 
(*) share based compensation included in the above  6,533   199,199 
         
Research and development expenses:        
Salaries and fees to officers  -   25,272 
 Share based compensation  -   - 

13

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

B. Balances with related parties and officers:

  As of June 30, 
  2021  2020 
         
Other accounts payables  173,526   258,782 

C. Other information:

1.On November 5, 2020, the board of directors of the Company appointed Mr. David Palach, to serve as Chief Executive Officer of the Company, effective as of the same date. In connection with Mr. Palach’s appointment, the parties entered into a Consulting Agreement pursuant to which the Company and Mr. Palach agreed upon, inter alia, the following engagement terms: (a) a monthly fee of $8,000, and (b) a grant of options to purchase shares of the Company’s Common Stock, which amount shall be determined by the Board on a future date. On June 17, 2021, the Board of Directors of the Company approved an amendment to the compensation of Mr. Palach, according to which he shall be entitled to a monthly fee of $14,000 and reimbursement of expenses of $500 per month. In addition, Mr. Palach shall receive a one-time grant of options to purchase shares of Common Stock of the Company representing 4.5% of the Company’s outstanding share capital as of the date of the approval. The terms of the grant have not yet been determined.
2.On June 17, 2021, the board of directors of the Company approved the compensation of Vered Raz Avayo as its Chief Financial Officer, according to which she shall be entitled to a monthly fee of $8,000 and reimbursement of expenses of $500 per month. In addition, Ms. Raz Avayo shall receive a one-time grant of options to purchase shares of Common Stock of the Company representing 1.5% of the Company’s outstanding share capital as of the date of the approval. The terms of the grant have not yet been determined.
3.On June 17, 2021, the board of directors of the Company approved the compensation of its Chairman of the Board, according to which the Chairman of the Board shall be entitled to a monthly fee of $5,000. In addition, the Chairman of the Board shall receive a one-time grant of options to purchase shares of Common Stock of the Company representing 1.5% of the Company’s outstanding share capital as of the date of the approval. The terms of the grant have not yet been determined.
4.On June 17, 2021, the board of directors of the Company approved the compensation for each non-executive member of the board, according to which the each such member shall be entitled to an annual fee of NIS 100,000 (approximately $30,500). In addition, each such member shall receive a one-time grant of options to purchase shares of Common Stock of the Company representing 0.25% of the Company’s outstanding share capital as of the date of the approval. The terms of the grant have not yet been determined.

14
 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 5 – RELATED PARTIES

A. Transactions and balances with related parties

  

Three months ended

March 31

 
  2020  2019 
       
General and administrative expenses:        
Directors compensation (*)  52,002   43,148 
Salaries and fees to officers (*)  78,003   26,438 
   130,005   69,586 
(*) share based compensation  39,054   14,811 
         
Research and development expenses:        
Salaries and fees to officers  25,272   38,139 
(*) share based compensation  -   4,387 

B. Balances with related parties and officers:

  As of March 31, 
  2020  2019 
Other accounts payables  227,309   128,327 

NOTE 68SUBSEQUENT EVENTS

On May 9, 2020,July 1, 2021, the Company entered into Securities Purchaseand a digital communication consultant signed an Addendum to a certain Service Agreement, withpreviously executed on October 20, 2020 (the “Original Agreement”), according to which the Company agreed to pay the consultant $15,000 as compensation for services rendered pursuant to the Original Agreement and to issue the consultant 14,285 shares of Common Stock of the Company. The Company estimates the value of the shares of Common Stock issued to be $143,279. In addition, the Company agreed to continue the Original Agreement for a period of an existing shareholder (the “Investor”),additional six months pursuant to which the Company sold to the Investor for an aggregate amountconsultant will receive a monthly fee of $100,000, 91,743 units at a price per unit of $1.09 (the “Units”), whereby each Unit consists of (i) one share of common stock of$10,000.

On July 12, 2021, the Company and (ii) one warrantsthe Chairman of the Board of Save Foods Ltd. entered into a Separation Agreement and Release according to purchase one sharewhich the consulting agreement previously executed with the former chairman was terminated effective as of Company’s common stockJuly 8, 2021. According to the Separation Agreement and Release, the Company would pay the amounts accrued to the former chairman under his consulting agreement and in addition the Company compensated the former chairman for the amounts owed to him during the 90 days notice following the termination of the Separation Agreement and Release and accelerate the vesting of all unvested options granted to the former chairman.

On August 5, 2021, the Company signed consulting agreement with an exercise price of $1.20a third party according to which the Consultant will provide the Company with strategic consulting and digital marketing services for a period of 36six months followingcommencing on September 1, 2021. As consideration for the issuance date.agreement, the Company agreed to pay the consultant a total fee of $301,000 and shall issue the consultant 12,000 shares of Common Stock of the Company.

15
 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our 2020 Annual Report on Form 10-K for the year ended December 31, 2019.Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our 2020 Annual Report for the fiscal year ended December 31, 2019 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysisanalysis. Furthermore, certain disclosures and references made herein apply to Save Foods Ltd., the subsidiary of Save Foods, Inc. The primary business activities and operations discussed herein are performed by Save Foods Ltd., whereas Save Foods, Inc. operates as a holding company and is the Registrant for purposes of this Quarterly Report on Form 10-Q..

We are a small and innovative company that develops, produces, and focuses on deliveringdevelop eco-friendly “green” solutions withinfor the food industry, aimed at improvingindustry. Our solutions are developed to improve the food safety and prolonging shelf life of fresh produce. We have developed a set of eco-friendlydo this by controlling human and “green” sanitizing solutions for fresh produce with high efficiency against humanplant pathogens, like Salmonella, E. coli,thereby reducing spoilage, and Listeria as well as against plant pathogens. This also allows us to ensurein turn, reducing food safety, extend shelf life and reduce food waste.loss.

Our technology isproducts are based on a proprietary blend of food acids which have a synergistic effect when combined with an oxidizer like hydrogen peroxide or per-acetic acid,certain types of oxidizing agent-based sanitizers and isfungicides at low concentrations. Our green products are capable of cleaning, sanitizing and controlling pathogens that renderon fresh produce unsafewith the goal of making them safer for human consumption or which lead to certain forms of decay in fruit and vegetable.

When used with hydrogen peroxide, our formulation creates an optimal environment for hydrogen peroxide and significantly extends the contact timeextending their shelf life by reducing their decay. One of the hydrogen peroxide withmain advantages of our products is that our active ingredients do not leave any toxicological residues on the target pathogens, which in due course ensures high levels of product safety. This formulation ultimately allows us to use a very low concentration of hydrogen peroxide, and generates a hostile environment for the pathogensfresh produce we treat. In contrary, by forming a temporary protective shield around the sanitized produce.

In addition, unlike conventional bactericides and fungicides, the active ingredients infresh produce we treat, our products make it difficult for pathogens to develop and potentially provide protection which also reduces cross-contamination.

Our shares of Common Stock are listed on the Nasdaq Capital Market under the symbol “SVFD.”

Due to the effects of COVID-19, as of the date of this report, some of our employees are on temporary leave without pay (furlough), including our Chief Technology Officer, and we have postponed some of our planned field tests due to restrictions on international travels. However, to date, we did not experience any material impact on our financial condition and results of operations due to COVID-19, and we do not leave any residues of toxicological concern on the treated produce; hydrogen peroxide rapidly decomposesexpect to water and oxygen and the ingredients of our acids blend are recognized by the United States Food and Drug Administration, or FDA, as GRAS, or Generally Recognized As Safe. More importantly, it significantly reduces the need for additional post-harvest applications such as conventional chemical bactericides and fungicides, which have regulatory limitations on maximum residue levels (MRL) allowed.

Further, our innovative solution provides packing house workers and other users of our products a safe and environmentally friendly, clean sanitizing process, which emissions do not irritate the eyes, skin or airways.

Our first application is in post-harvest treatment, and mainly targets fruit and vegetable packing houses that treat, clean and package citrus, avocado, papaya, mango, potatoes, onion and sweet potatoes. We are currently exploring additional applications for pre-harvest treatments and for the food industry, including fresh cut, fresh salads and processed foods. Our latest application is in greenhouses. We already conducted a proof of concept with a proven product safety and efficacy as applied towards a range of micro-greens and cannabis. While we have not completed a thorough study or examination of our technology vis-à-vis cannabis products, we believe our technology presents a unique solution for a variety of cannabis providers since it might help them significantly reduce yield losses that are caused by microbial infection. In addition, we believe that we may play a significant role in ensuring cannabis (both medicinal and recreational) is made safe for consumers, specifically with respect to reducing levels of pesticide residues and toxins produced by specific microbial infections and also eliminating the presence of human pathogens.

Critical Accounting Policies

Please see Note 2 of this Quarterly Report on Form 10-Q for the summary of significant accounting policies. Management’s Discussion and Analysis of Financial Condition and Results of Operation of our Annual Report on Form 10-K for the year ended December 31, 2019 (filed on March 30, 2020) with respect to our Critical Accounting Policies and Estimates. There have been no other material changes to our critical accounting policies and estimates since our Annual Report on Form 10-K for the year ended December 31, 2019.

Going Concern Uncertainty

The development and commercialization of our product will require substantial expenditures. We have not yet generatedexperience any material revenuesimpact on our overall liquidity positions and have incurred substantial accumulated deficit and negative operating cash flows. We currently have no sources of recurring revenue and are therefore dependent upon external sources for financing our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. Asoutlook as a result of the outbreak. Nevertheless, it is not possible at this time to estimate the full impact that the COVID-19 pandemic, the continued spread of COVID-19, and any additional measures taken by governments, health officials or by us in response to such spread, could have on our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. Thebusiness results of operations and financial statements do not include any adjustments that might result from the outcome of this uncertainty.condition.

 

16
 

Results of Operations

Components of Results of Operation

ComparisonRevenues and Cost of Revenues

Our total revenue consists of products and our cost of revenues consists of cost of products.

The following table discloses the breakdown of revenues and costs of revenues:

  

Six Months Ended

June 30,

  

Three Months Ended

June 30,

 
U.S. dollars in thousands, except share and per share data 2021  2020  2021  2020 
             
Revenues $177,477  $63,566  $54,403  $- 
Cost of revenues  (14,287)  (25,686)  (11,354)  (4,911)
Gross (loss) profit $163,190  $37,880  $43,049  $(4,911)

Operating Expenses

Our current operating expenses consist of three components — research and development expenses, selling and marketing expenses and general and administrative expenses.

Research and Development Expenses, net

Our research and development expenses consist primarily of salaries and related personnel expenses, share base compensation, professional fees and other related research and development expenses such as field tests.

  

Six Months Ended

June 30,

  

Three Months Ended

June 30,

 
U.S. dollars in thousands 2021  2020  2021  2020 
Salaries and related expenses $17,927  $38,643  $15,841  $- 
Share based compensation  31,344   33,636   13,428   19,050 
Professional fees  210,932   68,961   179,918   20,251 
Laboratory and field tests  7,376   77,525   1,116   42,920 
Other expenses  28,954   34,578   16,439   13,486 
Total $296,533  $253,343  $226,742  $95,707 

We expect that our research and development expenses will increase as we continue to develop our products and services, field trials and recruit additional research and development employees.

Selling and Marketing Expenses

Selling and marketing expenses consist primarily of salaries and related expenses, share based compensation and other expenses.

17

  

Six Months Ended

June 30,

  

Three Months Ended

June 30,

 
U.S. dollars in thousands 2021  2020  2021  2020 
Salaries and related expenses $3,414  $30,152  $2,637  $- 
Share based compensation  791   (22,366)  329   983 
Other expenses  29,204   28,962   15,746   6,828 
Total $33,409  $36,748  $18,712  $7,811 

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts including commercial validation pilots and recruit additional employees or contractor to support our selling and marketing efforts in our targeted geographical areas.

General and Administrative Expenses

General and administrative expenses consist primarily of professional services, share based compensation and other non-personnel related expenses.

  

Six Months Ended

June 30,

  

Three Months Ended

June 30,

 
U.S. dollars in thousands 2021  2020  2021  2020 
Salaries and related expenses $32,056  $-  $32,056  $- 
Professional services  1,277,693   208,439   1,123,805   88,935 
Share based compensation  112,738   205,087   47,309   162,756 
Legal expenses  20,753   36,582   10,687   18,155 
Other expenses  229,467   63,268   205,879   25,451 
Total $1,672,707  $513,376  $1,419,736  $295,297 

Three months ended June 30, 2021 compared to three months ended March 31,June 30, 2020 and 2019

Revenues.

Revenues for the three months ended March 31, 2020June 30, 2021 were $63,566, a decrease of $66,167, or 51%,$54,403, compared to total revenues of $129,733 for$0 during the three months ended March 31, 2019.June 30, 2020. The decreaseincrease is mainly a result of the Company’s efforts towards obtaining regulatory approval for itsour sale of new products, resulting in a temporary freeze of its sales in Israel and reductions in saleswhich we commenced in the U.S.fourth quarter of 2020.

We do not have backlogs or firm commitments from our clientscustomers for our products. Our sales might deteriorate if we fail to achieve clinicalcommercial success or obtain regulatory approval of any of our products.

Cost of RevenuesSales

Cost of revenuessales consists primarily of salaries, materials, transportation and overhead costs of manufacturing our products. Cost of revenues for the three months ended March 31, 2020June 30, 2021 was $20,775,$11,354, an increase of $13,266,$6,443, or 39%131%, compared to total cost of revenues of $34,041$4,911 for the three months ended March 31, 2019.June 30, 2020. The decreaseincrease is mainly a result of our increase in sales for the three months ended June 30, 2021.

18

Gross Profit

Gross profit for the three months ended June 30, 2021 was $43,049, an increase of $47,960, compared to gross loss of $4,911 for the three months ended June 30, 2020. The increase is mainly a result of the decreaseincrease in salaries and related expenses.revenues as detailed above.

Research and Development

Research and development expenses consist of salaries and related expenses, share base compensation, consulting fees, service providers’ costs, related materials and overhead expenses. Research and development expenses for the three months ended March 31, 2020June 30, 2021 were $157,636,$226,742, an increase of $25,810,$131,035, or 20%137%, compared to total research and development expenses of $131,826$95,707 for the three months ended March 31, 2019.June 30, 2020. The increase is mainly attributable to thean increase in professional fees and payrollsalary and related expenses offset by a decrease in share based compensation and in expenses associated with international travel and field trials which have been postponed due to research and development expenses.COVID-19.

Selling and Marketing Expenses

Selling and marketing expenses consist primarily of salaries and related costs for salesselling and marketing personnel, travel related expenses and services providers. Selling and marketing expenses for the three months ended March 31, 2020June 30, 2021 were $28,937, a decrease$18,712, an increase of $117,625,$10,901, or 80%139%, compared to total selling and marketing expenses of $146,562$7,811 for the three months ended March 31, 2019.June 30, 2020. The decreaseincrease is mainly attributable to the decreaseincrease in payroll expenses and service providers used in relation to selling and marketing activities.providers’ delivery costs associated with our sales.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related expenses including share based compensation and other professional services as well as other non-personnel related expenses such as legal expenses and directors and insurance costs. General and administrative expenses for the three months ended March 31, 2020June 30, 2021 were $218,079,$1,419,736, an increase of $54,931,$1,124,439, or 34%381%, compared to total general and administrative expenses of $163,148$295,297 for the three months ended March 31, 2019.June 30, 2020. The increase is mainly a result of the increase in professional expenses,services and share basedcompensation payable to directors following the listing of our Common Stock on the Nasdaq Capital Market, which occurred during the second quarter of 2021, offset partially by a decrease share-based compensation to our employees and service providers and directors.providers.

Financing Expenses, Net

Financing expenses,income, net for the three months ended March 31, 2020 was $7,202,June 30, 2021 were $120,916, a decreasechange of $6,300 or 47%$314,066, compared to total financing expenses of $13,502$193,149 for the three months ended March 31, 2019.June 30, 2020. The decrease is mainly a result of the decrease in compensation expenses related to the accrued interest and amortization expenses associated with our convertible loans which were fully converted during the three months ended June 30, 2021.

Total Comprehensive Loss

As a result of the foregoing, our total comprehensive loss for the three months ended June 30, 2021 was $1,481,580, compared to $577,045 for the three months ended June 30, 2020, an increase of $904,535, or 157%.

Six months ended June 30, 2021 compared to six months ended June 30, 2020

Revenues.

Revenues for the six months ended June 30, 2021 were $177,477, an increase of $113,911, or 179%, compared to total revenues of $63,566 for the six months ended June 30, 2020. The increase is mainly a result of currency exchange differences betweenour sales of new products, which we commenced in the US Dollarfourth quarter of 2020.

We do not have backlogs or firm commitments from our customers for our products. Our sales might deteriorate if we fail to achieve commercial success or obtain regulatory approval of any of our products.

Cost of Sales

Cost of sales consists primarily of salaries, materials, transportation and overhead costs of manufacturing our products. Cost of revenues for the six months ended June 30, 2021 was $14,287, a decrease of $11,399, or 44%, compared to total cost of revenues of $25,686 for the six months ended June 30, 2020. The decrease is mainly a result of the decrease in the overall cost of materials, due to our efforts to outsource production of our new solutions.

Gross Profit

Gross profit for the six months ended June 30, 2021 was $163,190, an increase of $125,310, or 331%, compared to gross profit of $37,880 for the six months ended June 30, 2020. The increase is mainly a result of the increase in revenues and the New Israeli Shekel.decrease in cost of revenues, as detailed above.

Research and Development

Research and development expenses consist of salaries and related expenses, share base compensation, consulting fees, service providers’ costs, related materials and overhead expenses. Research and development expenses for the six months ended June 30, 2021 were $296,533, an increase of $43,190, or 17%, compared to total research and development expenses of $253,343 for the six months ended June 30, 2020. The increase is mainly attributable to the increase in professional fees partially offset by a decrease in share based compensation and in payroll and decrease in expenses associated with international travel and field trials which have been postponed due to COVID-19.

Selling and Marketing Expenses

Selling and marketing expenses consist primarily of salaries and related costs for selling and marketing personnel, travel related expenses and services providers. Selling and marketing expenses for the six months ended June 30, 2021 were $33,409, a decrease of $3,339, or 9%, compared to total selling and marketing expenses of $36,748 for the six months ended June 30, 2020. The decrease is mainly attributable to the increase in payroll expenses and service providers used in relation to selling and marketing activities mainly associated with the termination of the employment of our former vice president of sales in February 2020 partially offset by an increase in share based compensation expenses.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related expenses including share based compensation, professional fees and other non-personnel related expenses such as legal expenses and directors and insurance costs. General and administrative expenses for the six months ended June 30, 2021 were $1,672,707, an increase of $1,159,331, or 226%, compared to total general and administrative expenses of $513,376 for the six months ended June 30, 2020. The increase is mainly a result of the increase in professional services and compensation payable to directors following the listing of our Common Stock on the Nasdaq Capital Market, which occurred during the second quarter of 2021, offset partially by a decrease share-based compensation to our employees and service providers.

Financing Expenses, Net

Financing expenses, net for the six months ended June 30, 2021 were $156,061, a decrease of $44,290, or 22%, compared to total financing expenses of $200,351 for the six months ended June 30, 2020. The decrease is mainly a result of the decrease in compensation expenses related to the accrued interest and amortization expenses associated with our convertible loans which were fully converted during the three months ended June 30, 2021.

Total Comprehensive Loss

As a result of the foregoing, our total comprehensive loss for the six months ended June 30, 2021 was $1,973,843, compared to $942,692 for the six months ended June 30, 2020, an increase of $1,031,151, or 109%.

19

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures. Since our inception through June 30, 2021, we have funded our operations principally with approximately $23,244,172 (net of issuance expenses) from the issuance of shares of our Common Stock, options and loans.

On May 13, 2021, we completed an underwritten public offering of 1,090,909 shares of Common Stock at a price to the public of $11.00 per share. The gross proceeds we received from this offering were $12,000,000 (net proceeds of $10,457,862) (the “Underwritten Offering”).

The table below presents our cash flows for the periods indicated:

 

17
  

Six Months Ended

June 30,

 
  2021  2020 
Net cash used in operating activities $(1,711,222) $(468,999)
         
Net cash provided by investing activities  4,375   (574)
         
Net cash provided by financing activities  10,761,603   214,009 
         
Effect of exchange rate changes on cash and cash equivalents and restricted cash  8,144   - 
         
Increase (decrease) in cash and cash equivalents $9,062,900  $(255,564)

As of March 31, 2020,June 30, 2021, we had cash of $180,003,$9,305,800, as compared to $290,815$242,900 as of December 31, 2019.2020. As of March 31, 2020,June 30, 2021, we had a working capital of $8,904,187, as compared to a negative working capital of $363,886, as compared to negative working capital of $199,212$290,062 as of December 31, 2019.2020. The increase in our cash balance is mainly attributable to the Underwritten Offering described above and proceeds from convertible loans.

In view of our cash balance following the above transactions, we anticipate that our cash balances will be sufficient to permit us to conduct our operations for at least a period of twelve months from the date of the issuance of these unaudited condensed consolidated financial statements. We may also satisfy its liquidity through the sale of its securities, either in public or private transactions.

If we are unable to obtain sufficient amounts of additional capital, we may be required to reduce the scope of our planned development, which could harm our business, financial condition and operating results. If we obtain additional funds by selling any of our equity securities or by issuing Common Stock to pay current or future obligations, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the Common Stock. If adequate funds are not available to us when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy.

Operating Activities

Net cash used in operating activities was $1,711,222 for the six months ended June 30, 2021, as compared to $468,999 for the six months ended June 30, 2020.

Investing Activities

Net cash provided by investing activities was $4,375 for the six months ended June 30, 2021, as compared to net cash used in investing activities of $574 for the six months ended June 30, 2020. The increase is mainly attributable to the increase in our net loss described above and payments to account payables, somewhat offset by share based compensation expenses and salesfunds in respect of our shares.

Net cash used in operating activities was $233,636 for the three months ended March 31, 2020, as compared to $326,894 for the three months ended March 31, 2019.

Net cash used in investing activities was $84 for the three months ended March 31, 2020, as compared to Net cash provided by $4,484 for the three months ended March 31, 2019. The increase is mainly attributable to employee rights upon termination.retirement.

Financing Activities

Net cash provided by financing activities was $122,740$10,761,603 for the threesix months ended March 31, 2020,June 30, 2021, as compared to $450,872$214,009 for the threesix months ended March 31, 2019.June 30, 2020. The decreaseincrease is mainly the result of a decrease in equity financing and proceeds from to the Underwritten Offering described above and convertible loans.

20

The spreadFinancial Arrangements

Since our inception, we have financed our operation primarily through proceeds from sales of COVID-19 throughoutour shares of Common Stock, convertible loan agreements and grants from the world may resultIsraeli Innovation Authority, formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry.

During January 2021, we entered into a series of convertible loan agreements with an aggregate principal amount of $274,000 that each bear interest at a rate of 5% per annum.

On May 11, 2021 and May 12, 2021, we issued an aggregate of 66,877 shares of Common Stock following the conversion of convertible promissory notes in the aggregate principal amount of $499,000 and of aggregated accrued interest amount of $11,211, at a periodconversion price of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations especially regarding its ability to obtain$7.63 per share.

On May 18, 2021, we closed the necessary finance to continue the Company’s operations. The extentUnderwritten Offering pursuant to which COVID-19 impactswe issued a total of 1,090,909 shares of our Common Stock at a purchase price of $11.00 per share. In connection with the Company’s business will depend on future developments,Underwritten Offering, we agreed to grant ThinkEquity, a division of Fordham Financial Management, Inc. (the “Underwriters”), a 45-day option to purchase up to 163,636 additional shares of Common Stock at the public offering price of $11.00 per share, less the underwriting discounts and commissions solely to cover over-allotments, which are highly uncertainwas not exercised by the Underwriters, and cannot be predicted, including new information which may emerge concerningto issue the severityUnderwriters a five-year warrants to purchase up to 54,545 shares of COVID-19 andCommon Stock, at a per share exercise price equal to 125% of the actions to contain COVID-19Underwritten Offering price per share of Common Stock, or treat its impact, among others.$13.75. The gross proceeds from the Underwritten Offering were approximately $12,000,000.

21

Off-Balance Sheet Arrangements

As of March 31, 2020,June 30, 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

Changes to Critical Accounting Policies and Estimates

Our critical accounting policies and estimates are set forth in our 2020 Annual Report.

ItemITEM 3. Quantitative and Qualitative Disclosures About Market Risk.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of March 31, 2020,June 30, 2021, the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, and due to certain material weaknesses identified by management, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of March 31, 2020.June 30, 2021.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting or in other factors identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.reporting.

1822
 

PART II-II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Not applicable.

ITEM 1A. RISK FACTORS.

Our business faces many risks, a number of which are described under the caption “Risk Factors” in our 2020 Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “2019 Annual Report”).Report. Other than as set forth below, there have been no material changes from the risk factors previously disclosed in our 20192020 Annual Report. The risks described in the 2019our 2020 Annual Report and below may not be the only risks we face. Other risks of which we are not yet aware, or that we currently believe are not material, may also materially and adversely impact our business operations or financial results. If any of the events or circumstances described in the risk factors contained in the 2019our 2020 Annual Report or described below occurs, our business, financial condition or results of operations could be adversely impacted and the value of an investment in our securities could decline. Investors and prospective investors should consider the risks described in the 2019our 2020 Annual Report and below, and the information contained under the caption “Forward-Looking Statements” and elsewhere in this Quarterly Report on Form 10-Q before deciding whether to invest in our securities.

The COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease, may materially and adversely affect our business and operations.

The recent outbreak of COVID-19, which originated in Wuhan, China, in December 2019, has since spread to multiple countries, including the United States, Israel and many European countries in which we operate. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. While COVID-19 is still spreading and the final implications of the pandemic are difficult to estimate at this stage, it is clear that it has affected the lives of a large portion of the global population. At this time, the pandemic has caused states of emergency to be declared in various countries, travel restrictions imposed globally, quarantines established in certain jurisdictions and various institutions and companies being closed. We are actively monitoring the pandemic and we are taking any necessary measures to respond to the situation in cooperation with the various stakeholders.

Based on guidelines provided by the Israeli Government, employers (including us) are also required to prepare and increase as much as possible the capacity and arrangement for employees to work remotely. In that regard, and in compliance with all applicable Israeli rules and guidelines, our offices have remained closed since the middle of March 2020, and all of our employees currently work remotely. In addition, COVID-19 infection of our workforce could result in a temporary disruption in our business activities, including manufacturing, and other functions.

The spread of an infectious disease, including COVID-19, may also result in the inability of our manufacturers to deliver components or finished products on a timely basis and may also result in the inability of our suppliers to deliver the parts required by our manufacturers to complete manufacturing of components or finished products. In addition, governments may divert spending from other budgeted resources as they seek to reduce and/or stop the spread of an infectious disease, such as COVID-19. Such events may result in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. The extent to which COVID-19 impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

None.

19

ITEM 6. EXHIBITS.

(a) The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.

Exhibit

Number

Description
NumberDescription
31.1*
31.1*Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
31.2*Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
32.1**Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS101.INS*Inline XBRL Instance Document
101.INS101.INS*Inline XBRL Taxonomy Extension Schema Document
101.CAL101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

* Filed herewith.

** Filed herewith.
**Furnished herewith.

2023
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2020August 16, 2021SAVE FOODS INC.
By:/s/ David Palach
Name:David Palach
Title:Chief Executive Officer
Save Foods, Inc.

By:/s/ Vered Raz Avayo
Name:Vered Raz Avayo
Title:Chief Financial Officer
  
By:/s/ Dan Sztybel
Name:Dan Sztybel
Title:Chief Executive Officer
Save Foods, Inc.
By:/s/ Shlomo Zakai
Name:Shlomo Zakai
Title:Chief Financial Officer
Save Foods, Inc.

2124